Crossmark

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

Crossref DOI link: https://doi.org/10.1186/s12885-020-6626-9

Published Online: 2020-02-24

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Adachi, Yuta https://orcid.org/0000-0003-1745-5039
Yanagimura, Naohiro

Suzuki, Chiaki

Ootani, Sakiko

Tanimoto, Azusa

Nishiyama, Akihiro

Yamashita, Kaname

Ohtsubo, Koushiro

Takeuchi, Shinji

Yano, Seiji
License Information

Text and Data Mining valid from 2020-02-24

Version of Record valid from 2020-02-24
More Information

Article History

Received: 4 April 2019

Accepted: 11 February 2020

First Online: 24 February 2020

Ethics approval and consent to participate

: Not applicable.

: The written informed consent was obtained from the patient for publication of this case report and any accompanying images. The copy of the informed consent is available.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below